R. B. KARGBO (USONA INSTITUTE, SAN LUIS OBISPO, USA)
Improved Synthesis of New FDA-Approved Treatment for KRAS G12C Mutation in Non-small Cell Lung Cancer

Synthesis of Sotorasib

**Significance:** Sotorasib (AMG 510, Lumakras) is the first ever FDA-approved drug that inhibits KRAS, a cancer target that has been termed “undruggable” even after over 40 years of cancer research. It was approved for KRAS G12C-mutated non-small cell lung cancer (NSCLC).

**Comment:** Urea D cyclized to give rac-dione E as a mixture of atropisomers in 41% yield over three steps. Chiral separation via the (+)-2,3-dibenzoyl-D-tartrate salt of rac-dione E led to M-dione M-F in 37% yield over two steps. For experimental details, see: WO 2021 097207 A1 and WO 2020 232130 A1.

SYNFACTS Contributors: Philip Kocienski
Synfacts 2021, 17(10), 1071 Published online: 17.09.2021
DOI: 10.1055/s-0040-1720181; Reg-No.: K05321SF

© 2021. Thieme. All rights reserved.
Georg Thieme Verlag KG, Rüdigerstraße 14, 70469 Stuttgart, Germany